<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887247</url>
  </required_header>
  <id_info>
    <org_study_id>REDUCE-CONCURRENT</org_study_id>
    <nct_id>NCT03887247</nct_id>
  </id_info>
  <brief_title>Reducing Concurrent Opioid-Benzodiazepine Prescriptions</brief_title>
  <official_title>Reducing Concurrent Opioid-Benzodiazepine Prescriptions Through Provider Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Services Administration (GSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Walter Reed National Military Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this effort is to use informative e-mails to improve the process of&#xD;
      prescribing of opioids and benzodiazepines within the National Capital Region/Military Health&#xD;
      System (NCR/MHS), with the aim of decreasing concurrent opioid and benzodiazepine&#xD;
      prescribing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this effort is to use low-cost informative e-mails to improve the process of&#xD;
      prescribing of opioids and benzodiazepines within the National Capital Region/Military Health&#xD;
      System (NCR/MHS), with the aim of decreasing concurrent opioid and benzodiazepine&#xD;
      prescribing. Both the VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain&#xD;
      (2017) and the CDC Guideline for Prescribing Opioids for Chronic Pain (2016) strongly&#xD;
      recommend against the concurrent use of opioids and benzodiazepines. Taken together, these&#xD;
      drugs could cause respiratory depression, enhanced sedation, and death. The intervention&#xD;
      population will be prescribers and primary care managers associated with patients who have&#xD;
      recently received concurrent prescriptions of opioids and benzodiazepines. Using a randomized&#xD;
      approach, we will allocate the NCR/MHS providers associated with patients with concurrent&#xD;
      prescriptions for opioids and benzodiazepines to one of two conditions:&#xD;
&#xD;
        1. E-mail alert - A messaging approach, in which we will send encrypted emails to the&#xD;
           patient's opioid and benzodiazepine prescriber(s) and primary care manager that identify&#xD;
           the concurrent prescriptions and detail the patient's prescription history, inform them&#xD;
           of the VA/DoD guideline and risk to patient, and provide action steps and relevant&#xD;
           resources. When multiple providers are involved, the email message will also encourage&#xD;
           coordination across providers and provide relevant contact information&#xD;
&#xD;
        2. As-Usual - An as-usual approach, in which providers are not sent messages. These&#xD;
           providers can access patient information through the MHS Opioid Registry as before.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overlapping Days</measure>
    <time_frame>90 days</time_frame>
    <description>Overlapping days of opioids and benzodiazepines, determined using the dates of service and days supply of the prescription drug fills</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Days</measure>
    <time_frame>90 days</time_frame>
    <description>Days of opioids received</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Benzodiazepine Days</measure>
    <time_frame>90 days</time_frame>
    <description>Days of benzodiazepines received</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2234</enrollment>
  <condition>Adverse Drug Effect of Opioids</condition>
  <condition>Adverse Drug Effect of Benzodiazepines</condition>
  <arm_group>
    <arm_group_label>E-Mail Alert</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>As-Usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>As-usual (no email) approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>E-mail Alert</intervention_name>
    <description>Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.</description>
    <arm_group_label>E-Mail Alert</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient had an overlapping opioid-benzodiazepine prescription&#xD;
&#xD;
          -  At least one of the patient's providers (opioid prescribers, benzodiazepine&#xD;
             prescribers, and/or PCM) is in the NCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a cancer diagnosis&#xD;
&#xD;
          -  Patient is receiving palliative care&#xD;
&#xD;
          -  Patient is under 18&#xD;
&#xD;
          -  Patient was previously allocated to a study condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E Brutcher, PharmD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed National Military Medical Center and Uniformed Services University of the Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Sim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Defense Health Agency</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elana Safran, MPP</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Services Administration (GSA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Sacarny, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Services Administration and Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Steffel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Services Administration and Northeastern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher J Spevak, MD, MPH, JD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed National Medical Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Care coordination</keyword>
  <keyword>Opioid</keyword>
  <keyword>Benzodiazepine</keyword>
  <keyword>Behavioral science</keyword>
  <keyword>Behavioral economics</keyword>
  <keyword>Nudge</keyword>
  <keyword>Fragmentation of care</keyword>
  <keyword>Concurrent prescribing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

